VLDL receptor gene therapy for reducing atherogenic lipoproteins

Area of Science:

• Cardiovascular Disease Research
• Lipid Metabolism and Genetics

Background:

• Cardiovascular disease (CVD) management primarily targets low-density lipoprotein cholesterol (LDL-C).
• Residual CVD risk persists due to high triglyceride (TG) and lipoprotein(a) (Lp(a)) levels, even with lowered LDL-C.
• The VLDL receptor (VLDLR) is crucial for lipoprotein metabolism but typically not expressed in the liver.

Purpose of the Study:

• To review the function of VLDL receptor (VLDLR).
• To explore the potential of hepatic VLDLR expression for managing atherogenic lipid disorders.
• To discuss VLDLR as a target for genetic medicine to address residual CVD risk.

Main Methods:

• Literature review of VLDLR function in lipoprotein metabolism.
• Analysis of VLDLR's role in binding and internalizing TG-rich lipoproteins and Lp(a).
• Evaluation of the therapeutic potential of liver-targeted VLDLR gene expression.

Main Results:

• VLDLR binds and internalizes apoE-containing TG-rich lipoproteins and Lp(a).
• Hepatic VLDLR expression can promote the clearance of these atherogenic particles from circulation.
• Targeting VLDLR in the liver offers a novel strategy for managing residual CVD risk.

Conclusions:

• VLDLR plays a significant role in lipoprotein clearance.
• Liver-specific VLDLR expression presents a promising therapeutic avenue for atherogenic lipid disorders.
• Genetic medicine targeting hepatic VLDLR could address unmet needs in CVD prevention.